|
(2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine
|
DB06994 |
|
|
S-(3-Iodobenzyl)Glutathione
|
DB04341 |
|
|
Patupilone
|
DB03010 |
[Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.] |
|
Adenosine-5'-(Dithio)Phosphate
|
DB03011 |
|
|
7-((Carboxy(4-Hydroxyphenyl)Acetyl)Amino)-7-Methoxy-(3-((1-Methyl-1h-Tetrazol-5-Yl)Thio)Methyl)-8-Oxo-5-Oxa-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid
|
DB04342 |
|
|
AC-100
|
DB05671 |
[AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). It is being developed by Acologix, Inc.] |
|
2-[(Dioxidophosphoranyl)oxy]benzoate
|
DB04340 |
|
|
ATL-104
|
DB05670 |
[ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.] |
|
(S)-propane-1,2-diol
|
DB04349 |
[A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.] |
|
3,4-Dimethylaniline
|
DB03018 |
|
|
4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
|
DB03019 |
|
|
Ustekinumab
|
DB05679 |
[Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.[A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice.[A187349] It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways.[A187346]
The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines.[L9392] The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA®.] |
|
3-Dehydroshikimate
|
DB04347 |
|
|
CRA_1801
|
DB03016 |
|
|
Lauric acid
|
DB03017 |
[Lauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression. Lauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses.] |
|
Taurocholic acid
|
DB04348 |
[The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.] |
|
SLx-4090
|
DB05678 |
[SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]] |
|
Lumichrome
|
DB04345 |
|
|
6-hydroxy-1,6-dihydro purine nucleoside
|
DB03015 |
|
|
(2r,4s)-2-Methyl-2,3,3,4-Tetrahydroxytetrahydrofuran
|
DB04346 |
|
